[Form 4] Bio-Techne Corp. Insider Trading Activity

Rhea-AI Filing Summary

Bio-Techne Corp. (TECH) insider William Geist reported multiple equity transactions on 08/15/2025 reflecting compensation vesting and a small sale. The filing shows the acquisition of 2,623 common shares via vested restricted stock units at $0, and a disposition of 803 shares sold at $53.60, leaving 15,112 shares beneficially owned after the sale. The report also lists numerous outstanding stock options and performance-based awards, including 24,758 newly acquired stock options exercisable at $53.60 with an 08/15/2035 expiration, other options at strike prices from $74.91 to $100.39, and several restricted and performance RSU pools totaling tens of thousands of shares that vest on various future dates if conditions are met. Transactions were signed by an attorney-in-fact on 08/19/2025.

Insights

Compensation & Governance Specialist

TL;DR: Mostly routine equity compensation and vesting; awards align executive pay with long-term performance.

The Form 4 indicates standard executive compensation activity: vesting of restricted stock units and grants or reporting of multiple option tranches with staggered vesting and performance conditions. Material elements include the conversion of RSUs into 2,623 shares and the reporting of large pools of performance RSUs and options that extend to 2035, which suggests multi-year retention incentives. The small sale of 803 shares at $53.60 appears to be a minor liquidity action and does not materially alter overall ownership. Overall, these items are governance-typical and aimed at alignment and retention rather than signaling a corporate event.

Securities Analyst

TL;DR: No material shift in ownership or control; transactions are compensation-related and unlikely to affect valuation directly.

The reporting shows beneficial ownership remaining at 15,112 shares after a modest sale. Significant outstanding derivative positions are detailed: for example, 24,758 options at a $53.60 strike expiring 08/15/2035 and other option tranches aggregating over 100,000 underlying shares across strikes from $53.60 to $100.39. Because many awards are time- or performance-vested, the immediate dilution risk is remote and tied to future vesting and performance certification. The filing lacks any indication of extraordinary transfers or corporate actions that would be material to investors today.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Geist William

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, PROTEIN SCIENCES

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		2,623	A	$0	15,915	D
Common Stock	08/15/2025		F		803	D	$53.6	15,112	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$100.39							(2)	02/01/2029	Common Stock	15,912		15,912	D
Stock Options (Right to Buy)	$94.52							(3)	08/15/2029	Common Stock	29,600		29,600	D
Performance Restricted Stock Units	(1)							(4)	(4)	Common Stock	9,074		9,074	D
Performance Stock Options (Right to Buy)	$84.61							(4)	(4)	Common Stock	24,424		24,424	D
Stock Options (Right to Buy)	$84.61							(5)	08/15/2030	Common Stock	30,059		30,059	D
Restricted Stock Units	(1)							(6)	(6)	Common Stock	9,911		9,911	D
Performance Restricted Stock Units	(1)							(7)	(7)	Common Stock	15,738		15,738	D
Restricted Stock Units	(1)	08/15/2025		M			2,623	(8)	(8)	Common Stock	2,623	$0	5,246	D
Stock Options (Right to Buy)	$74.91							(9)	08/15/2034	Common Stock	21,204		21,204	D
Performance Restricted Stock Units	(1)	08/15/2025		A		19,355		(10)	(10)	Common Stock	19,355	$0	19,355	D
Restricted Stock Units	(1)	08/15/2025		A		9,678		(11)	(11)	Common Stock	9,678	$0	9,678	D
Stock Options (Right to Buy)	$53.6	08/15/2025		A		24,758		(12)	08/15/2035	Common Stock	24,758	$0	24,758	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

2. Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2025, and options to purchase 3,976 shares vest on each of 2/1/2024 and 2/1/2026.

3. Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

5. Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.

6. 9,911 restricted stock units vest on 11/1/2025.

7. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

8. 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.

9. Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

11. 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

12. Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.

	/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.